Sanofi introduces diabetes drug Soliqua in India
The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year.
Sanofi India on Tuesday said it has launched its diabetes drug Soliqua in the country. The company introduced the medication after receiving the marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) earlier last year.
Soliqua is a once-daily injectable combination drug containing insulin, glargine 100 units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist.
Also Read: Sterlite Power bags projects worth Rs 2,500 crore in Q4
It is available at a therapy cost of Rs 1,850 per pen.
"The inclusion of Soliqua to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively," Sanofi India Head Diabetes Business Unit Cyrus Aibara said in a statement.
Soliqua is indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Special Live Trading Session on Saturday: Know why BSE, NSE will remain open on May 18; check timings
Gold and Silver rate today (May 16, 2024): Yellow metal futures subdued; white metal hits record high breaches Rs 87,000 mark
SBI Senior Citizen FD Rates: What Rs 1 lakh, Rs 3 lakh, and 5 lakh investments will give you in 1-, 3- and 5-year FDs
Top 7 SIP Mutual Funds in 1 Year: What Rs 10,000, Rs 15,000, and Rs 20,000 SIPs have given in each fund
01:29 PM IST